18F-2-fluoro-2-deoxy-D-glucose positron emission tomography scanning affects surgical management in selected patients with high-risk, operable breast carcinoma

Department of Surgery, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, New York, 10021, USA.
Annals of Surgical Oncology (Impact Factor: 3.94). 06/2006; 13(5):677-84. DOI: 10.1245/ASO.2006.03.035
Source: PubMed

ABSTRACT The role of positron emission tomography (PET) scanning in determining the extent of disease in patients with breast cancer has not been defined. We investigated the utility of (18)F-2-fluoro-2-deoxy-D: -glucose (FDG)-PET scanning compared with conventional imaging with computed tomographic scanning and bone scanning in determining the extent of disease in patients with high-risk, operable breast cancer.
This was a prospective study of patients who presented to Memorial Sloan-Kettering Cancer Center for operative treatment of breast cancer. Eighty eligible patients were enrolled and underwent computed tomographic chest, abdomen, pelvis, and bone scans, followed by FDG-PET. Changes in treatment based on scan findings were recorded by the operating surgeons. Imaging findings were verified by biopsy or long-term follow-up.
Eight (10%) of 80 patients were found to have metastatic disease that was seen on both conventional imaging and PET. Four additional patients (5%) had additional foci of disease on PET that affected treatment decisions. No patient had findings on conventional imaging alone. Conventional imaging studies resulted in a higher number of findings that generated additional tests and biopsies that ultimately had negative results (17% vs. 5% for PET). There was a statistically significant difference in specificity for PET compared with conventional imaging (P = .01).
Conventional imaging and PET were equally sensitive in detecting metastatic disease in patients with high-risk, operable breast cancer, but PET generated fewer false-positive results. FDG-PET scanning should be further studied in this setting and considered in the preoperative evaluation of selected patients with breast cancer.

  • Source
    • "This disease subset is likely to become a distinct entity due to the diffusion of imaging methods with higher sensitivity for distant metastases in the workup of clinically localized breast cancer. In the past, a number of reports have suggested that the incidence of distant metastases in breast cancer patients candidates to surgery could be as high as 20% when CT-PET scanning is used [18] [19]. More recently, a prospective study involving 254 women with clinical stages II and III breast cancer evaluated the diagnostic yield of CT-PET scanning [20]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Five to 10% of women with newly diagnosed breast cancer have synchronous metastases (de novo stage IV). A further 20% will develop metastases during follow-up (recurring stage IV). We compared the clinical outcomes of women with HER2-positive metastatic breast cancer (MBC) receiving first-line trastuzumab-based therapy according to type of metastatic presentation. Retrospective analysis of 331 MBC patients receiving first-line trastuzumab-based treatment. Response rates (RR) were compared by the chi-square test. Time-to progression (TTP) and overall survival (OS) curves were compared by the log-rank test. Cox-proportional hazards models were used to study predictors of PFS and OS, including the type of metastatic presentation. Seventy-seven patients (23%) had de novo stage IV disease. Forty-six of these patients underwent surgery of the primary ("de novo/surgery"). Response rates to first-line trastuzumab-based therapy and median progression-free survival did not differ in patients with "recurring", "de novo/surgery" and "de novo" without surgery ("de novo/no surgery) stage IV breast cancer. However, women with "de novo/surgery" stage IV breast cancer had the longest median OS (60 months), and those with "de novo/no surgery" stage IV breast cancer the shortest (26 months). For women with recurring metastatic breast cancer median OS was 40 months (overall log-rank test, p < 0.01). Multivariate analysis confirmed these findings. Our analysis shows that response rates and PFS to first-line trastuzumab-based therapy do not differ significantly between de novo and recurring stage IV, HER2 positive breast cancer. The observed difference in OS favoring women with de novo stage IV disease submitted to surgery of the primary tumor could be the result of a selection bias.
    Breast (Edinburgh, Scotland) 11/2013; DOI:10.1016/j.breast.2013.10.005 · 2.58 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Most malignant skeletal lesions initiate intramedullary. As the intramedullary malignant deposit enlarges, the surrounding bone undergoes osteoclastic and osteoblastic activity. Tumor cells may destroy bone directly or produce mediators that stimulate reabsorption by osteoclasts.1Based on the balance between the two processes, the radiographic appearance of a malignant skeletal lesion may be lytic, blastic, or mixed.2Detection of malignant skeletal involvement is based on either direct visualization of tumor cells or of the secondary reaction of the bone to the present malignant cells.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Skeletal imaging of oncologic patients is aimed at identifying early bone involvement, to determine the extent of the disease, and to monitor the response to therapy [1]. Detection of malignant bone involvement is either direct, by visualization of tumoral infiltration, or indirect, by detecting the reaction of bone to the presence of malignant cells. The vast majority of bone metastases initiate as bone marrow micrometastases. As the lesion enlarges within the marrow, the surrounding bone undergoes osteoclastic (resorptive) and osteoblastic (depositional) activity. Based on the balance between these two processes, metastasis can be lytic, sclerotic (blastic), or mixed [2, 3]. In nuclear medicine, 18F-fluordeoxyglucose (18F-FDG), a PET tracer, directly accumulates in tumor cells and may therefore identify malignant bone involvement even at early stages, when confined to the marrow, before cortical bone reaction has occurred, while increased accumulation of 99mTc-MDP-methylene diphosphonate (the tracer used for bone scintigraphy) or 18F-fluoride, a bone-seeking PET tracer, depends on the presence of secondary reactive osteoblastic changes [3, 4].
Show more


Available from